The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

2021170 citationsJournal Articlediamond Open Access

Authors

Sara E. Oliver · Brunswick (United States)

Julia W. Gargano · Brunswick (United States)

Heather M. Scobie · Brunswick (United States)

Megan Wallace · Brunswick (United States)

Stephen C. Hadler · Brunswick (United States)

Jessica W. T. Leung · Brunswick (United States)

Amy Blain ·

Abstract

the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Janssen COVID-19 (Ad.26.COV2.S) vaccine (Janssen Biotech, Inc, a Janssen Pharmaceutical company, Johnson & Johnson; New

Topics & Keywords

Vaccine Coverage and Hesitancy SARS-CoV-2 and COVID-19 Research Hepatitis Viruses Studies and Epidemiology

Publication Details

Published in: MMWR Morbidity and Mortality Weekly Report

Volume 70, Issue 9, pp. 329-332

DOI: 10.15585/mmwr.mm7009e4

Field-Weighted Citation Impact: 20.04

Command Palette

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

Authors

Abstract

Topics & Keywords

Publication Details